Phase 3 Atrial Fibrillation Trial, Recruiting (NCT05174052)

Phase 3 Atrial Fibrillation Trial, Recruiting NCT05174052 Sponsor: University of Oklahoma Condition: Atrial Fibrillation

Printed from Voxsanity (voxsanity.com.au) — NCT05174052 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Atrial Fibrillation

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with diabetes mellitus (DM)
You experience episodes of an irregular heartbeat that come and go (known as paroxysmal atrial fibrillation, or AF)

Who may not be able to join:

You have Type 1 diabetes
You have symptoms of low blood pressure, or your systolic (top number) blood pressure reading is below 90mmHg
Your kidneys are not working well, based on a blood test result showing poor kidney filtering ability (eGFR below 30mL/minute/1.73m²) (confirm with trial site)
You have had a lower leg or foot amputation in the past
You have had an allergic reaction to a medication called Dapagliflozin
You are currently taking a type of diabetes medication known as an SGLT2 inhibitor (confirm with trial site if unsure whether your medication falls into this category)
You are currently pregnant
You are currently taking medications used to control heart rhythm (anti-arrhythmic drugs)
You are currently scheduled to have, or are undergoing, a procedure called catheter ablation to treat your heart rhythm

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zain Ul Abideen Asad, MD, University of Oklahoma

Phone: 405-271-8001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05174052

Sponsor: University of Oklahoma

Phase: Phase 3

Status: Recruiting

Condition: Atrial Fibrillation

Trial contact: 405-271-8001

More information: https://clinicaltrials.gov/study/NCT05174052

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with diabetes mellitus (DM)
You experience episodes of an irregular heartbeat that come and go (known as paroxysmal atrial fibrillation, or AF)

Who may not be able to join:

You have Type 1 diabetes
You have symptoms of low blood pressure, or your systolic (top number) blood pressure reading is below 90mmHg
Your kidneys are not working well, based on a blood test result showing poor kidney filtering ability (eGFR below 30mL/minute/1.73m²) (confirm with trial site)
You have had a lower leg or foot amputation in the past
You have had an allergic reaction to a medication called Dapagliflozin
You are currently taking a type of diabetes medication known as an SGLT2 inhibitor (confirm with trial site if unsure whether your medication falls into this category)
You are currently pregnant
You are currently taking medications used to control heart rhythm (anti-arrhythmic drugs)
You are currently scheduled to have, or are undergoing, a procedure called catheter ablation to treat your heart rhythm

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

University of Oklahoma

Registry

ClinicalTrials.gov

Start date

1 June 2022

Est. completion

1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The effect of Dapagliflozin on change in burden of atrial fibrillation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov